Keywords
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
Selected data models

You must log in to select data models for download or further analysis.

11927 Search results.

DACAPO-II Study - Interhospitaltransport

- 5/9/17 - 6 forms, 7 itemgroups, 34 items, 1 language
Itemgroups: Interhospitaltransport, Besatzung waehrend des Transports, Qaulifikationen des Transportarztes?, Qualifikationen erster Rettungsassistent, Kommunikation und Dauer, Komplikationen waehrend des Transports, Wenn Transportmitelverzoegerung = ja, was war der Grund fuer die Verzoegerun
Das schwere akute Lungenversagen des Erwachsenen: Einfluss der Versorgungsqualität und individueller Patientenmerkmale auf die gesundheitsbezogene Lebensqualität bei Überlebenden (DACAPO) Surviving ARDS: the influence of quality of care and individual patient characteristics on health-related quality of life (DACAPO)

Externe Klinik

7 itemgroups, 96 items

Studienzentrum

4 itemgroups, 44 items

Verlegung vom Studienzentrum

1 itemgroup, 18 items

Demographische Daten

1 itemgroup, 11 items
1 other form meeting the search is available in the detailed view.

GSK 100262 Clinical Study Report Demography

- 5/17/17 - 1 form, 2 itemgroups, 4 items, 1 language
Itemgroups: Date of assessment, Demography
GSK 100262 Clinical Study Report Demography

End of study LenaMain-Study - Trial End

- 3/17/16 - 1 form, 10 itemgroups, 94 items, 1 language
Itemgroups: End of study, Survival Status, Monthly control visit with response evaluation, Parameter of multiple myeloma, Vital signs, Laboratory:Protein electrophoresis, Laboratory:Hematology, Laboratory:serum chemistry, Quality of life, Hematotoxicity CTC
A randomised comparison of daily 25 mg versus 5 mg lenalidomide as maintenance therapy after high-dose therapy and autologous stem cell transplantation in patients with multiple myeloma. Protocol-Code: RV-MM-PI-280 EudraCT-Number: 2007-003945-33 Author: Claus Schreiber Review: Gerd Felder Approval of CRF: Prof. Dr. med. G. Kobbe (LKP) Release for MDM: Prof. Gattermann, Düsseldorf (26.1.2016) Principal Investigator „LenaMain“-Studie: Prof. Roland Fenk, Düsseldorf Coordinating center for clinical trial Medical faculty of University Hospital Heinrich-Heine-University Scientific Director: Herr Dr. J. Grebe Moorenstrasse 5 40225 Düsseldorf Tel.: +49 (0) 211-81-19701 Fax: +49 (0) 211-81-19702

End of study PETAL Study NCT00554164 - End of study

- 11/23/16 - 1 form, 4 itemgroups, 25 items, 2 languages
Itemgroups: Comorbidity, Discontinuation, Adverse event, Footer module
Positronen-Emissionstomographie-gesteuerte Therapie aggressiver Non-Hodgkin-Lymphome (PETAL-Studie) Universitätsklinikum Essen (UK Essen) EudraCT-Nummer: 2006-001641-33 NCT00554164

End of Study: End of Study Post-Study Period [DS_2] NCT01117584

- 2/4/17 - 1 form, 1 itemgroup, 5 items, 1 language
Itemgroup: General Information
NCT01117584 Astellas Phase 2b, Double-Blind, Randomized, Multicenter, Parallel Group, Placebo-Controlled, Dose-Finding Study to Evaluate the Efficacy, Safety and Tolerability of a 12- Week Treatment with ASP1941 in Combination with Metformin in Patients with Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Alone.

Study Conclusion End of Study Ropinirole NCT00632736 - Study Conclusion End of Study

- 7/30/17 - 1 form, 2 itemgroups, 6 items, 1 language
Itemgroups: STUDY CONCLUSION, Pregnancy information
Study part: Study Conclusion End of Study.An Open-Label Extension phase 3 Study with REQUIP (ropinirole) CR for Subjects from Studies 101468/165, 101468/168 and 101468/169 Patient Level Data. Study ID:101468/248, Clinical Study ID: 101468/248.

Nerventra Study Study drug dispensing and return

- 6/8/16 - 1 form, 3 itemgroups, 22 items, 1 language
Itemgroups: Demographic Information, Drug dispensed, Drug dispensing and return
Nerventra Study (Eudra CT 2007-003226-19) Study MS-LAQ-301: A multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study, to evaluate the safety, tolerability and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis (RRMS)

TEST Study - ODM-Form

- 6/18/18 - 1 form, 2 itemgroups, 5 items, 1 language
Itemgroups: Lab Identification Log, Physical Examination
TEST Study

On-Study - Waldenstroms Macroglobulinemia - On-Study Form - 2273908v3.0 - Waldenstroms Macroglobulinemia - On-Study Form

- 1/9/15 - 1 form, 5 itemgroups, 57 items, 1 language
Itemgroups: CRF Header, Waldenstrom's: Form Administration, Waldenstrom's: Disease Description, Waldenstrom's: Prior Treatment, Waldenstrom's: Relapsed Disease
Waldenstrom's Macroglobulinemia - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6795205-A4D9-0CD9-E034-0003BA12F5E7

On-Study - Hodgkins Lymphoma - On-Study Form - 2271441v3.0 - Hodgkins Lymphoma - On-Study Form

- 1/9/15 - 1 form, 9 itemgroups, 127 items, 1 language
Itemgroups: CRF Header, Lymphoma: Form Administration, Hodgkin's Lymphoma: Disease Description, Hodgkin's Lymphoma: Baseline Hematology/Chemistry, Lymphoma: Prior Treatment, Lymphoma: Relapsed Disease, Lymphoma: Cardiac Evaluation, Lymphoma: Pulmonary Evaluation, Lymphoma: Endocrine Evaluation
Hodgkin's Lymphoma - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D5EC9E8E-4085-0DC0-E034-0003BA12F5E7

On-Study - Multiple Myeloma - On-Study Form - 2274325v3.0 - Multiple Myeloma - On-Study Form

- 1/9/15 - 1 form, 4 itemgroups, 58 items, 1 language
Itemgroups: CRF Header, Myeloma: Form Administration, Myeloma: Disease Description, Myeloma: Prior Treatment
Multiple Myeloma - On-Study Form Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=D6E1DCBD-670E-54A2-E034-0003BA12F5E7

On-Study - Intervention Administration (Blinded Study) - 2802926v1.0 - Intervention Administration (Blinded Study)

- 1/9/15 - 1 form, 3 itemgroups, 18 items, 1 language
Itemgroups: DCP Template Header, Intervention Administration (Blinded Study), DCP Template Footer
The Division of Cancer Prevention's intervention administration (blinded study) case report form (CRF) template. Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=5C0DAF39-FA2E-52F4-E044-0003BA3F9857